Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results.
Anemia
ECOG
Everolimus
Metastatic kidney cancer
RCC
mTOR inhibitor
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
10
05
2017
accepted:
20
09
2017
pubmed:
14
10
2017
medline:
13
2
2019
entrez:
14
10
2017
Statut:
ppublish
Résumé
Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose. Physical and laboratory examinations and imaging tests were performed monthly and every 3 months, respectively. Median progression-free survival (PFS) was 5.4 months. Median overall survival (OS) was 16.2 months. PFS and OS results were more favorable in patients with ECOG 0-1 (p
Identifiants
pubmed: 29027615
doi: 10.1007/s12253-017-0317-0
pii: 10.1007/s12253-017-0317-0
doi:
Substances chimiques
Antineoplastic Agents
0
Everolimus
9HW64Q8G6G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-156Références
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
N Engl J Med. 2003 Aug 28;349(9):847-58
pubmed: 12944570
J Clin Oncol. 2004 Feb 1;22(3):454-63
pubmed: 14752067
Genes Dev. 2004 Aug 15;18(16):1926-45
pubmed: 15314020
Lancet. 2008 Aug 9;372(9637):449-56
pubmed: 18653228
Urol Oncol. 2008 Sep-Oct;26(5):543-9
pubmed: 18774471
Cancer. 2010 Sep 15;116(18):4256-65
pubmed: 20549832
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
Eur J Cancer. 2012 Feb;48(3):324-32
pubmed: 21803569
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Eur J Cancer. 2012 Feb;48(3):333-9
pubmed: 22209391
Cancer Treat Rev. 2013 Jun;39(4):366-74
pubmed: 22832091
Ann Oncol. 2014 Sep;25 Suppl 3:iii49-56
pubmed: 25210086
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
BMC Cancer. 2015 Apr 18;15:303
pubmed: 25925846
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Ann Oncol. 2016 Sep;27(suppl 5):v58-v68
pubmed: 27664262